$PDSB
PDS Biotechnology Corp

2019 Q4 Form 10-Q Financial Statement

#000114036119019968 Filed on November 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $410.0K $3.000M $3.450M
YoY Change -88.12% -15.49% -34.78%
% of Gross Profit
Research & Development $1.350M $1.834M $490.0K
YoY Change 175.51% 845.22% -95.48%
% of Gross Profit
Depreciation & Amortization $10.00K $30.00K $40.00K
YoY Change -75.0% -25.0% -20.0%
% of Gross Profit
Operating Expenses $1.760M $5.847M $3.930M
YoY Change -55.22% 723.26% -75.62%
Operating Profit -$5.847M
YoY Change 723.26%
Interest Expense $30.00K $0.00 $180.0K
YoY Change -83.33% -100.0% -148.65%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.560M -$5.750M -$5.870M
YoY Change -22.32% 34.66% -64.4%
Income Tax -$380.0K -$2.780M
% Of Pretax Income
Net Earnings -$4.180M -$5.752M -$3.090M
YoY Change 35.28% 708.71% -77.77%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$791.7K -$1.095M -$1.968M
COMMON SHARES
Basic Shares Outstanding 5.779M 5.247M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.20M $17.40M $34.60M
YoY Change -64.74% -52.72% -60.73%
Cash & Equivalents $12.16M $17.41M $103.7K
Short-Term Investments
Other Short-Term Assets $2.300M $700.0K $1.000M
YoY Change 130.0% 250.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.47M $18.13M $122.1K
YoY Change 11748.87% -51.12% -99.86%
LONG-TERM ASSETS
Property, Plant & Equipment $21.05K $26.93K $29.51K
YoY Change -28.66% -94.61% -99.13%
Goodwill
YoY Change
Intangibles $2.974M $1.223M $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $12.80K
YoY Change -100.0% -100.0% -87.2%
Total Long-Term Assets $21.05K $1.250M $42.31K
YoY Change -50.24% 108.32% -98.79%
TOTAL ASSETS
Total Short-Term Assets $14.47M $18.13M $122.1K
Total Long-Term Assets $21.05K $1.250M $42.31K
Total Assets $14.49M $19.38M $164.4K
YoY Change 8712.97% -48.58% -99.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.198M $1.489M $1.308M
YoY Change -8.4% 148.16% -70.28%
Accrued Expenses $1.098M $1.297M $601.9K
YoY Change 82.37% 44.07% -88.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $2.794M $3.644M $1.909M
YoY Change 46.3% -45.61% -85.2%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.794M $3.644M $1.909M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.794M $3.800M $2.231M
YoY Change 25.23% -43.28% -92.61%
SHAREHOLDERS EQUITY
Retained Earnings -$28.94M -$23.83M -$21.94M
YoY Change 31.9%
Common Stock $1.742K $1.742K $19.87M
YoY Change -99.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.70M $15.58M -$2.066M
YoY Change
Total Liabilities & Shareholders Equity $14.49M $19.38M $164.4K
YoY Change 8712.97% -48.58% -99.82%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q4
OPERATING ACTIVITIES
Net Income -$4.180M -$5.752M -$3.090M
YoY Change 35.28% 708.71% -77.77%
Depreciation, Depletion And Amortization $10.00K $30.00K $40.00K
YoY Change -75.0% -25.0% -20.0%
Cash From Operating Activities -$5.520M -$4.320M -$2.170M
YoY Change 154.38% -52.84% -76.52%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $270.0K $0.00
YoY Change
Cash From Investing Activities $270.0K $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.520M -4.320M -2.170M
Cash From Investing Activities 270.0K 0.000 0.000
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -5.250M -4.320M -2.170M
YoY Change 141.94% -52.84% -76.54%
FREE CASH FLOW
Cash From Operating Activities -$5.520M -$4.320M -$2.170M
Capital Expenditures $0.00
Free Cash Flow -$2.170M
YoY Change -76.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
PDS Biotechnology Corp
dei Entity Central Index Key
EntityCentralIndexKey
0001472091
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5778850
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1412951
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1488961
CY2018Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
8000
CY2019Q3 us-gaap Accrued Rent Current
AccruedRentCurrent
443868
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
601889
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1296606
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
421617
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
230337
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
39414792
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
19311529
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
46000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
638610
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
29705
us-gaap Depreciation
Depreciation
93814
us-gaap Depreciation
Depreciation
21415
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
120206
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
49336
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
41691
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2893658
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1668660
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
342105
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
41691
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2893658
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
120207
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
49336
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103695
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17406608
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-2.88
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60
CY2018Q4 us-gaap Assets
Assets
344323
CY2019Q3 us-gaap Assets
Assets
19383496
CY2018Q4 us-gaap Assets Current
AssetsCurrent
260323
CY2019Q3 us-gaap Assets Current
AssetsCurrent
18133567
CY2019Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-3.15
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-8.28
CY2018Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-1.01
CY2019Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-16552729
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-13621882
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-39799838
CY2018Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-4976379
CY2019Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-3.15
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-2.88
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-8.28
CY2018Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-1.01
CY2019Q3 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
0
CY2018Q3 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
0
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
0
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
11939331
CY2019Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
17406608
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
103695
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
17302913
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-33215
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103695
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
175884
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17406608
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
142669
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
29106512
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.10
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.87
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00033
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00033
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3417187
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5278850
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3417187
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5278850
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1128
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
1742
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-711208
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2820763
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5751610
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2016932
CY2019Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
3573760
CY2018Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
30000
CY2019Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
32953
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2019Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
157000
CY2018Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
0
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1753155
CY2018Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-944445
CY2018Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2019Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-944445
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-310951
CY2019Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-310951
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1450429
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
516202
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3068581
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9358429
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q3 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2018Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
0
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-1211939
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
244305
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1521516
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-900622
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
146562
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-34366
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1908520
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
41692
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1223000
CY2018Q3 us-gaap Interest Expense
InterestExpense
942
us-gaap Interest Expense
InterestExpense
2705
CY2019Q3 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
606
us-gaap Interest Paid Net
InterestPaidNet
1022
us-gaap Interest Paid Net
InterestPaidNet
606
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
95787
us-gaap Investment Income Interest
InvestmentIncomeInterest
294694
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4
us-gaap Investment Income Interest
InvestmentIncomeInterest
14
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
268999
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
603924
CY2019Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
603924
CY2019Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
58665
CY2018Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
15644
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
46931
CY2019Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
38365
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
344323
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19383496
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3643899
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2014840
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Note 1 <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8211;</font> Nature of Operations</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman';">PDS Biotechnology Corporation, a Delaware corporation (the &#8220;Company,&#8221; &#8220;PDS&#8221; or the &#8220;combined company&#8221;), is a clinical stage immuno-oncology company with a growing pipeline of clinical-stage immunotherapies to treat cancer at various stages, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.</font>&#160; <font style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman';">All of PDS&#8217;s products are based on the proprietary Versamune</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"><font style="background-color: #FFFFFF;">&#174;</font></sup><font style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman';"> platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.&#160; The Versamune</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"><font style="background-color: #FFFFFF;">&#174;</font></sup><font style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman';">-based immunotherapies may be used as monotherapies or in combination with other agents.&#160; PDS is initially prioritizing the development of the Versamune</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"><font style="background-color: #FFFFFF;">&#174;</font></sup><font style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman';">-based products as combination therapies to be administered with other potentially synergistic agents such as FDA-approved therapeutic or immunotherapeutic agents and promising therapeutic agents still in clinical development.</font></div><div><br /></div><div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">On March 15, 2019, the Company, then operating as Edge Therapeutics, Inc. (&#8220;Edge&#8221;), completed its reverse merger with privately held PDS Biotechnology Corporation (&#8220;Private PDS&#8221;), pursuant to and in accordance with the terms of the Agreement and Plan of Merger, dated as of November 23, 2018, as amended on January 24, 2019, by and among the Company, Echos Merger Sub, a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), and Private PDS, whereby Private PDS merged with and into Merger Sub, with Private PDS surviving as the Company&#8217;s wholly-owned subsidiary (the &#8220;Merger&#8221;).</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font>In connection with and immediately following completion of the Merger, the Company effected a 1-for-20 reverse stock split (the &#8220;Reverse Stock Split&#8221;) and changed its corporate name from Edge Therapeutics, Inc. to PDS Biotechnology Corporation, and Private PDS changed its name to PDS Operating Corporation.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">For accounting purposes, the Merger is treated as a &#8220;reverse acquisition&#8221; under generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and Private PDS is considered the accounting acquirer. Accordingly, <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">upon consummation of the Merger, the historical financial statements of Private PDS became the Company's historical financial statements, and the historical financial statements of Private PDS are included in the comparative prior periods. See &#8220;Note 4 &#8211; Reverse Merger&#8221; for more information on the Merger. </font>As part of the Merger, the Company acquired all of Edge's assets relating to current and future research and development.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">From the Company's inception, it has devoted substantially all of its efforts to business planning, engaging regulatory, manufacturing and other technical consultants, acquiring operating assets, planning and executing clinical trials and raising capital.</div></div>
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12553599
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1251949
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
750000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-5751610
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-711208
us-gaap Net Income Loss
NetIncomeLoss
-2016932
us-gaap Net Income Loss
NetIncomeLoss
-2820763
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29106512
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1218734
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
15793638
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
0
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1200000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
271283
CY2019Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
98648
us-gaap Operating Expenses
OperatingExpenses
15054182
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
5847397
us-gaap Operating Expenses
OperatingExpenses
2014241
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
710270
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1015
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-710270
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5847397
us-gaap Operating Income Loss
OperatingIncomeLoss
-15054182
us-gaap Operating Income Loss
OperatingIncomeLoss
-2014241
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1400000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1200000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12800
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
46674
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0
us-gaap Payments For Restructuring
PaymentsForRestructuring
1211939
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
156628
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
726959
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
750000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1229370
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
750000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29508
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26929
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
0
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
10636
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0233
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1834371
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
194068
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
563812
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4751308
CY2018Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2019Q3 us-gaap Restructuring Reserve
RestructuringReserve
858332
CY2019Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
858332
CY2018Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
0
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21013174
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23833937
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y0M29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M20D
us-gaap Share Based Compensation
ShareBasedCompensation
49336
us-gaap Share Based Compensation
ShareBasedCompensation
2893658
CY2019Q3 us-gaap Share Price
SharePrice
5.76
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8360
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9222
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8360
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8988
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.30
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.91
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0275
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0149
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0275
CY2019Q3 us-gaap Shares Issued
SharesIssued
0
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
32953
CY2019Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
1599178
CY2019Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
4461
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
29704
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
48930
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
15793638
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25407
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25407
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
750000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1076894
CY2018Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
275000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-1700517
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
15582597
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
20605615
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-807608
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-609528
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-1078755
CY2019Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4729153
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 36pt; vertical-align: top; align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(B)</td><td style="width: auto; vertical-align: top; text-align: justify;"><div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Use of estimates:</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3253085
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4729153
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3346237
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5246829
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3253085
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3346237
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5246829
CY2019Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
489863
CY2018Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
54269
CY2019Q1 pdsb Conversion Of Stock Shares Converted
ConversionOfStockSharesConverted
0.3262
CY2019Q3 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
132538
CY2018Q4 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
71329
CY2019Q1 pdsb Class Of Warrant Or Right Number Of Warrants Issued
ClassOfWarrantOrRightNumberOfWarrantsIssued
34192
pdsb Consultant Agreements Expenses
ConsultantAgreementsExpenses
0
CY2019Q3 pdsb Consultant Agreements Expenses
ConsultantAgreementsExpenses
0
pdsb Consultant Agreements Expenses
ConsultantAgreementsExpenses
299000
CY2018Q3 pdsb Consultant Agreements Expenses
ConsultantAgreementsExpenses
181500
CY2019Q3 pdsb Number Of Equity Based Compensation Plans
NumberOfEquityBasedCompensationPlans
5
pdsb Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
39067927
CY2018Q3 pdsb Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
5162697
CY2019Q3 pdsb Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
15964969
pdsb Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
25171754
CY2018Q3 pdsb Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
99963
pdsb Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
99963
pdsb Stock Issued During Period Value Antidilution Protection
StockIssuedDuringPeriodValueAntidilutionProtection
0
CY2019Q3 pdsb Stock Issued During Period Shares Equity Transaction
StockIssuedDuringPeriodSharesEquityTransaction
100654
CY2019Q3 pdsb Stock Issued During Period Value Equity Transaction
StockIssuedDuringPeriodValueEquityTransaction
603924
pdsb Stock Issued During Period Value Equity Transaction
StockIssuedDuringPeriodValueEquityTransaction
603924
CY2019Q3 pdsb Remaining Lease Payments
RemainingLeasePayments
665802
CY2019Q3 pdsb Number Of Installments For Remaining Lease Payment
NumberOfInstallmentsForRemainingLeasePayment
3
CY2019Q3 pdsb Operating Lease Percentage Of Remaining Payments Required To Be Paid To Terminate Lease
OperatingLeasePercentageOfRemainingPaymentsRequiredToBePaidToTerminateLease
0.5
CY2019Q3 pdsb Common Stock Purchase Agreement Shares That Can Be Sold Percentage
CommonStockPurchaseAgreementSharesThatCanBeSoldPercentage
0.1999
pdsb Common Stock Purchase Agreement Threshold Consecutive Trading Days
CommonStockPurchaseAgreementThresholdConsecutiveTradingDays
P10D
pdsb Common Stock Purchase Agreement Threshold Closing Sale Prices
CommonStockPurchaseAgreementThresholdClosingSalePrices
3
CY2019Q3 pdsb Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2019Q1 pdsb Fractional Shares Paid Out In Cash
FractionalSharesPaidOutInCash
235
CY2019Q1 pdsb In The Money Shares Paid Out In Cash
InTheMoneySharesPaidOutInCash
753

Files In Submission

Name View Source Status
0001140361-19-019968-index-headers.html Edgar Link pending
0001140361-19-019968-index.html Edgar Link pending
0001140361-19-019968.txt Edgar Link pending
0001140361-19-019968-xbrl.zip Edgar Link pending
ex10_1.htm Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10q.htm Edgar Link pending
pdsb-20190930.xml Edgar Link completed
pdsb-20190930.xsd Edgar Link pending
pdsb-20190930_cal.xml Edgar Link unprocessable
pdsb-20190930_def.xml Edgar Link unprocessable
pdsb-20190930_lab.xml Edgar Link unprocessable
pdsb-20190930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending